Abstract
Heparin has been used as an anticoagulant for decades. Recently, attention has been drawn to the nonanticoagulant activities of heparin. Experimentally and clinically those non-anticoagulant properties of heparin inhibit inflammation and metastatic spread of tumor cells. On the molecular level, heparin inhibits the function, expression and/or synthesis of adhesion molecules, cytokines, angiogenic factors and complement. However, despite a similar anticoagulant activity, those non-anticoagulant effects of heparin differ greatly among the different heparin preparations. The same holds true for the most common adverse events of heparin treatment. The incidence of immune mediated heparin-induced thrombocytopenia and cutaneous hypersensitivity responses is greatly, but not exclusively, influenced by the heparin preparation used. As the structure-function relationship of the anti-inflammatory and anti-metastatic effects of heparins are understood in more detail, and as the risk profile of different heparin preparations regarding the induction of adverse events have been identified, we propose to use the different heparin preparations according to the individual needs of each patient.
Keywords: Inflammation, metastasis, heparin, glycosaminoglycans, lymphocyte homing, chemokines, angiogenesis, complement, adverse events
Current Drug Discovery Technologies
Title: Therapeutic Use of Heparin beyond Anticoagulation
Volume: 6 Issue: 4
Author(s): Ralf J. Ludwig
Affiliation:
Keywords: Inflammation, metastasis, heparin, glycosaminoglycans, lymphocyte homing, chemokines, angiogenesis, complement, adverse events
Abstract: Heparin has been used as an anticoagulant for decades. Recently, attention has been drawn to the nonanticoagulant activities of heparin. Experimentally and clinically those non-anticoagulant properties of heparin inhibit inflammation and metastatic spread of tumor cells. On the molecular level, heparin inhibits the function, expression and/or synthesis of adhesion molecules, cytokines, angiogenic factors and complement. However, despite a similar anticoagulant activity, those non-anticoagulant effects of heparin differ greatly among the different heparin preparations. The same holds true for the most common adverse events of heparin treatment. The incidence of immune mediated heparin-induced thrombocytopenia and cutaneous hypersensitivity responses is greatly, but not exclusively, influenced by the heparin preparation used. As the structure-function relationship of the anti-inflammatory and anti-metastatic effects of heparins are understood in more detail, and as the risk profile of different heparin preparations regarding the induction of adverse events have been identified, we propose to use the different heparin preparations according to the individual needs of each patient.
Export Options
About this article
Cite this article as:
Ludwig J. Ralf, Therapeutic Use of Heparin beyond Anticoagulation, Current Drug Discovery Technologies 2009; 6 (4) . https://dx.doi.org/10.2174/157016309789869001
DOI https://dx.doi.org/10.2174/157016309789869001 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Advances in the Pathogenesis and Progression of Barrett’s Esophagus
Current Molecular Medicine Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine EDITORIAL [Hot topic: Tissue Fibrosis (Guest Editor: Shizuya Saika)]
Endocrine, Metabolic & Immune Disorders - Drug Targets A Network Biology Approach for Assessing the Role of Pathologic Adipose Tissues in Insulin Resistance Using Meta-analysis of Microarray Datasets
Current Genomics Maternal and Fetal Outcomes in Iranian Patients with Systemic Lupus Erythematosus: A Five-Year Retrospective Study of 60 Pregnancies
Current Rheumatology Reviews Ultrasound Assisted Synthesis of 3-(het)aryl Isocoumarin Derivatives and their in vitro Pharmacological Evaluation
Mini-Reviews in Medicinal Chemistry DIMming Ovarian Cancer Growth
Current Drug Targets 13-lncRNAs Signature to Improve Diagnostic and Prognostic Prediction of Hepatocellular Carcinoma
Combinatorial Chemistry & High Throughput Screening Selected Phytochemicals to Combat Lungs Injury: Natural Care
Combinatorial Chemistry & High Throughput Screening The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Neuroprotective Effects of an Erythropoietin-Derived Peptide in PC1 2 Cells under Oxidative Stress
CNS & Neurological Disorders - Drug Targets The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology NAP (Davunetide) Provides Functional and Structural Neuroprotection
Current Pharmaceutical Design Identifying the Mechanisms and Molecular Targets of Guchang Zhixie Pills on Ulcerative Colitis: Coupling Network Pharmacology with GEO Database and Experiment Verification
Combinatorial Chemistry & High Throughput Screening Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cystic Fibrosis (CF), Pseudomonas aeruginosa, CFTR and the CF Glycosylation Phenotype: A Review and Update
Current Organic Chemistry Hypoxia-Inducible Factor-1 as Regulator of Angiogenesis in Rheumatoid Arthritis - Therapeutic Implications
Current Medicinal Chemistry Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology Epigallocatechin-3-Gallate Prevents Autoimmune-Associated Down- Regulation of p21 in Salivary Gland Cells Through a p53-Independent Pathway
Inflammation & Allergy - Drug Targets (Discontinued)